{"filing":{"accession_number":"0001193125-26-257501","cik":"0000873303","ticker":"SRPT","company_name":"Sarepta Therapeutics, Inc.","form":"8-K","filing_date":"2026-06-04","report_date":null,"primary_document":"d88936d8k.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/873303/000119312526257501/d88936d8k.htm"},"events":[{"id":6818,"run_id":5975,"accession_number":"0001193125-26-257501","anchor_item_number":"5.07","event_type":"shareholder_vote_results","event_domain":"governance","is_material":true,"confidence":0.98,"summary":"Sarepta held its Annual Meeting of Stockholders on June 4, 2026, with stockholders voting on five proposals: election of five Class I directors (Douglas S. Ingram, Hans Wigzell, Kathryn J. Boor, Michael Chambers, and Deirdre Connelly), advisory approval of named executive officer compensation, approval of the 2026 Equity Incentive Plan, approval of the 2026 Employee Stock Purchase Plan, and ratification of KPMG as independent auditor. All proposals passed with substantial majorities.","company_name":"Sarepta Therapeutics, Inc.","ticker":"SRPT","filing_date":"2026-06-04","form":"8-K","submitted_at":null,"items":[{"id":4348,"accession_number":"0001193125-26-257501","item_number":"5.02","item_title":"Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.","event_type":"exec_compensation","event_domain":"governance","is_material":true,"confidence":0.92,"reasoning":"The disclosure centers on stockholder approval of two new equity compensation plans: the 2026 Equity Incentive Plan (6.3M shares) and the 2026 Employee Stock Purchase Plan (1.5M shares), both of which supersede prior plans. This is a material compensatory arrangement disclosure under Item 5.02(e), as it establishes the framework for equity awards to directors, officers, and employees going forward.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-06-05T04:58:31.984731+00:00","company_name":"","ticker":null,"filing_date":""},{"id":4349,"accession_number":"0001193125-26-257501","item_number":"5.07","item_title":"Submission of Matters to a Vote of Security Holders.","event_type":"shareholder_vote_results","event_domain":"governance","is_material":true,"confidence":0.98,"reasoning":"This Item 5.07 disclosure presents the final voting results from Sarepta's Annual Meeting of Stockholders held on June 4, 2026, covering five proposals: election of Class I directors (Douglas S. Ingram, Hans Wigzell, Kathryn J. Boor, Michael Chambers, and Deirdre Connelly), advisory approval of named executive officer compensation, approval of the 2026 Equity Incentive Plan, approval of the 2026 Employee Stock Purchase Plan, and ratification of KPMG as independent auditor. All proposals passed with substantial majorities, and the disclosure includes detailed vote tallies (For, Against, Abstain, Broker Non-Votes) for each matter, which is the core content required by Item 5.07.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-06-05T04:58:31.984731+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":4348,"accession_number":"0001193125-26-257501","item_number":"5.02","item_title":"Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.","event_type":"exec_compensation","event_domain":"governance","is_material":true,"confidence":0.92,"reasoning":"The disclosure centers on stockholder approval of two new equity compensation plans: the 2026 Equity Incentive Plan (6.3M shares) and the 2026 Employee Stock Purchase Plan (1.5M shares), both of which supersede prior plans. This is a material compensatory arrangement disclosure under Item 5.02(e), as it establishes the framework for equity awards to directors, officers, and employees going forward.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-06-05T04:58:31.984731+00:00","company_name":"Sarepta Therapeutics, Inc.","ticker":"SRPT","filing_date":"2026-06-04"},{"id":4349,"accession_number":"0001193125-26-257501","item_number":"5.07","item_title":"Submission of Matters to a Vote of Security Holders.","event_type":"shareholder_vote_results","event_domain":"governance","is_material":true,"confidence":0.98,"reasoning":"This Item 5.07 disclosure presents the final voting results from Sarepta's Annual Meeting of Stockholders held on June 4, 2026, covering five proposals: election of Class I directors (Douglas S. Ingram, Hans Wigzell, Kathryn J. Boor, Michael Chambers, and Deirdre Connelly), advisory approval of named executive officer compensation, approval of the 2026 Equity Incentive Plan, approval of the 2026 Employee Stock Purchase Plan, and ratification of KPMG as independent auditor. All proposals passed with substantial majorities, and the disclosure includes detailed vote tallies (For, Against, Abstain, Broker Non-Votes) for each matter, which is the core content required by Item 5.07.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-06-05T04:58:31.984731+00:00","company_name":"Sarepta Therapeutics, Inc.","ticker":"SRPT","filing_date":"2026-06-04"}]}